Earnings Briefing | Pets at Home | Stabilisation confirmed as retail improves, but the lower earnings base still matters

Earnings Briefing | Pets at Home

Stabilisation confirmed as retail improves, but the lower earnings base still matters

Scoring: +1 ●●●●●

Impact on forecasts: FY26 group underlying PBT -2%; FY27 group underlying PBT 0%; DPS -25-35%

Time saved: 40 min

FY26 landed close to the reset base: Group underlying PBT of c£92m was a small miss versus the 1 March consensus snapshot, but broadly where Q3 had already pointed. This reads more like confirmation of stabilisation than another warning.
Retail finally improved in H2: Positive H2 like-for-like sales, volume growth and a better Q4 imply a much stronger second half, even though full-year retail PBT of c£30m is still roughly 60% below FY25.
Vet remains the earnings anchor: Vet PBT of c£83m is up about 9% year on year, and the CMA outcome is framed as benign, leaving retail execution as the main swing factor for FY27-28.
The bigger estimate change is dividend, not PBT: Management is comfortable with FY27 consensus, so near-term PBT estimates may not move much, but the new 50% payout ratio should put clear pressure on DPS forecasts, partly offset by higher buybacks.

Financials | FY26 landed close to plan as retail improved

FY26 pre-close: headline numbers versus consensus

Metric	Consensus	Actual	Beat/miss	Comments
Group underlying PBT	94.3	~92.0	Miss (-2.5%)	Best match to the disclosed underlying PBT; likely the main on-the-day comparison.
Non-underlying costs	8.3	~7.0	Beat (lower by 16%)	Slightly better than expected and mildly supportive for statutory EPS and cash.
Implied statutory PBT	87.3	~85.0	Miss (-2.6%)	Derived as underlying PBT less non-underlying costs; lower-confidence bridge.

Consensus snapshot dated 1 Mar 2026; the company had previously referenced FY26 consensus around £93m at Q3.
Retail and vet figures are disclosed on a PBT basis and are not cleanly comparable with consensus segment operating-profit lines.
All figures in £m unless stated.

FY26 profit mix: retail still explains the downturn

Metric	FY25 actual	FY26 current	Change
Group underlying PBT	133.0	~92.0	c(31%)
Retail underlying PBT	72.9	~30.0	c(59%)
Vet Group PBT	75.9	~83.0	c+9%
Central + insurance (implied)	(15.8)	~(21.0)	Worse

Central + insurance is implied from disclosed group, retail and vet profit figures.
All figures in £m unless stated.

This was essentially an in-line pre-close: the c£92m group outcome is only modestly below the 1 March consensus snapshot and consistent with management’s Q3 framing that FY26 would end in the low-£90ms.
Retail improved materially in H2: full-year retail PBT of c£30m implies c£26.5m in H2 versus just £3.5m in H1. At group level, FY26 implies c£55.8m of H2 PBT versus £36.2m in H1. Positive H2 like-for-like sales, volume growth and sequential Q4 improvement make the turnaround message credible, albeit from a very depressed base.
Vet again carried the group: the vet business delivered another year of profit growth despite slower activity growth, helped by higher average transaction values and Care Plan growth.
Recovery is less clean below the segment headlines: the disclosed group, retail and vet figures imply roughly £21m of central plus insurance losses versus £15.8m in FY25, so not all of the profit base is yet moving the right way.
Cash finished slightly better than feared: year-end net debt of c£20m is better than the c£25m indicated at H1 despite £85m returned through dividends and buybacks, though it still marks a move away from FY25 net cash.

Outlook | FY27 points to modest recovery, not upgrade

FY27 read-across: limited PBT change, bigger capital return reset

Item	Current statement	Consensus / model implication
FY27 group underlying PBT	Management is “comfortable” with current analyst consensus; ~80% of energy and FX hedged	Broadly neutral on the company’s cited £99m consensus; a touch soft versus the 1 Mar snapshot of £103.6m
Retail	Price investments implemented, £20m of overhead savings completed, many benefits still ahead	Supports recovery, but evidence still points to gradual margin rebuild rather than a sharp snapback
Vet / CMA	No adverse impact expected from the CMA final report	Helpful for confidence in outer-year vet assumptions and for removing a visible overhang
Dividend / buybacks	Dividend rebased to a 50% payout ratio; total cash returned unchanged	DPS estimates look too high; more of the return shifts to buybacks, which may be modestly supportive for EPS via a lower share count

The company cites current FY27 consensus at £99m, versus £103.6m in the 1 Mar snapshot.
All figures in £m unless stated.

The message is “no new downside,” not “upgrade”: FY26 started with guidance of £115-125m of underlying PBT and is ending around £92m. Today’s statement suggests the downgrade cycle has stopped, not that a strong recovery has begun.
Our bottom-up model broadly agrees for FY27: the independent base case is £99m of underlying PBT for FY27 and £110m for FY28, so there is no obvious near-term mismatch versus company-cited consensus.
Retail margin remains the key outer-year swing factor: roughly 50bps of retail PBT margin is worth c£6-7m of group PBT, making gross margin recovery and savings drop-through the critical issues for the prelims.
Dividend estimates may move more than earnings: DPS near 11.1p in the 1 March snapshot looks stale under a strict 50% payout policy; the offset is a larger buyback rather than lower total shareholder returns.

What people might miss | Improved tone came with materially thinner disclosure

This was a deliberately narrow statement: there were no full-year sales figures, no customer KPI table, no online growth disclosure, no insurance update and no management quote. The release is built to anchor investors on profit stabilisation and consensus comfort, not to prove demand quality in detail.
That narrower disclosure cuts both ways: the company sounds more realistic and therefore more credible than it did before the FY26 reset, but prelims need to bring back hard sales and customer data if the retail improvement is to be fully trusted.
The missing customer KPIs are notable: earlier reporting acknowledged methodology changes around Pets Club and later shifted emphasis to transactions as a better health indicator. Until FY26 results restore clearer data, analysts may want to treat broad customer-health claims cautiously.
Insurance has moved into the background: a business previously highlighted as an adjacency is absent from this release, even though the implied central plus insurance drag worsened year on year. That reinforces that core retail repair is the priority.

This content is provided for general information only. It is not investment research and does not constitute advice, a recommendation, or a solicitation to trade. Primer can make mistakes - please verify independently.

Driven by AI, built by analysts.